These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 24998080)

  • 1. Sitagliptin use in patients with diabetes and heart failure: a population-based retrospective cohort study.
    Weir DL; McAlister FA; Senthilselvan A; Minhas-Sandhu JK; Eurich DT
    JACC Heart Fail; 2014 Dec; 2(6):573-82. PubMed ID: 24998080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. All-cause mortality and cardiovascular effects associated with the DPP-IV inhibitor sitagliptin compared with metformin, a retrospective cohort study on the Danish population.
    Scheller NM; Mogensen UM; Andersson C; Vaag A; Torp-Pedersen C
    Diabetes Obes Metab; 2014 Mar; 16(3):231-6. PubMed ID: 24020750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hospitalisation for heart failure and mortality associated with dipeptidyl peptidase 4 (DPP-4) inhibitor use in an unselected population of subjects with type 2 diabetes: a nested case-control study.
    Giorda CB; Picariello R; Tartaglino B; Marafetti L; Di Noi F; Alessiato A; Costa G; Gnavi R
    BMJ Open; 2015 Jun; 5(6):e007959. PubMed ID: 26048211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study.
    Eurich DT; Simpson S; Senthilselvan A; Asche CV; Sandhu-Minhas JK; McAlister FA
    BMJ; 2013 Apr; 346():f2267. PubMed ID: 23618722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sitagliptin After Ischemic Stroke in Type 2 Diabetic Patients: A Nationwide Cohort Study.
    Chen DY; Wang SH; Mao CT; Tsai ML; Lin YS; Su FC; Chou CC; Wen MS; Wang CC; Hsieh IC; Hung KC; Cherng WJ; Chen TH
    Medicine (Baltimore); 2015 Jul; 94(28):e1128. PubMed ID: 26181549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do dipeptidyl peptidase-4 inhibitors increase the risk of heart failure?
    Bhatt DL; Cavender MA
    JACC Heart Fail; 2014 Dec; 2(6):583-5. PubMed ID: 24998081
    [No Abstract]   [Full Text] [Related]  

  • 7. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
    Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
    Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baseline characteristic differences between patients prescribed sitagliptin vs. other oral antihyperglycemic agents: analysis of a US electronic medical record database.
    Zhang Q; Rajagopalan S; Mavros P; Engel SS; Davies MJ; Yin D; Radican L
    Curr Med Res Opin; 2010 Jul; 26(7):1697-703. PubMed ID: 20465367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of new-onset heart failure in patients using sitagliptin: a population-based cohort study.
    Eurich DT; Weir DL; Simpson SH; Senthilselvan A; McAlister FA
    Diabet Med; 2016 May; 33(5):621-30. PubMed ID: 26206341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial.
    Pratley RE; Nauck M; Bailey T; Montanya E; Cuddihy R; Filetti S; Thomsen AB; Søndergaard RE; Davies M;
    Lancet; 2010 Apr; 375(9724):1447-56. PubMed ID: 20417856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No increased risk of hospitalization for heart failure for patients treated with dipeptidyl peptidase-4 inhibitors in Taiwan.
    Chang CH; Chang YC; Lin JW; Caffrey JL; Wu LC; Lai MS; Chuang LM
    Int J Cardiol; 2016 Oct; 220():14-20. PubMed ID: 27389437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Database.
    Fadini GP; Avogaro A; Degli Esposti L; Russo P; Saragoni S; Buda S; Rosano G; Pecorelli S; Pani L;
    Eur Heart J; 2015 Sep; 36(36):2454-62. PubMed ID: 26112890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sitagliptin and cardiovascular outcomes in diabetic patients with chronic kidney disease and acute myocardial infarction: A nationwide cohort study.
    Chen DY; Wang SH; Mao CT; Tsai ML; Lin YS; Chou CC; Wen MS; Wang CC; Hsieh IC; Hung KC; Chen TH
    Int J Cardiol; 2015 Feb; 181():200-6. PubMed ID: 25528312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics of patients prescribed sitagliptin and other oral antihyperglycaemic agents in a large US claims database.
    Cai B; Katz L; Alexander CM; Williams-Herman D; Girman CJ
    Int J Clin Pract; 2010 Nov; 64(12):1601-8. PubMed ID: 20946268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach.
    Xu L; Man CD; Charbonnel B; Meninger G; Davies MJ; Williams-Herman D; Cobelli C; Stein PP
    Diabetes Obes Metab; 2008 Dec; 10(12):1212-20. PubMed ID: 18476982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial.
    McGuire DK; Van de Werf F; Armstrong PW; Standl E; Koglin J; Green JB; Bethel MA; Cornel JH; Lopes RD; Halvorsen S; Ambrosio G; Buse JB; Josse RG; Lachin JM; Pencina MJ; Garg J; Lokhnygina Y; Holman RR; Peterson ED;
    JAMA Cardiol; 2016 May; 1(2):126-35. PubMed ID: 27437883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dipeptidyl peptidase-4 inhibitors and cardiovascular risks in patients with pre-existing heart failure.
    Ou SM; Chen HT; Kuo SC; Chen TJ; Shih CJ; Chen YT
    Heart; 2017 Mar; 103(6):414-420. PubMed ID: 27647170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sitagliptin and the risk of hospitalization for heart failure: a population-based study.
    Wang KL; Liu CJ; Chao TF; Huang CM; Wu CH; Chen SJ; Yeh CM; Chen TJ; Lin SJ; Chiang CE
    Int J Cardiol; 2014 Nov; 177(1):86-90. PubMed ID: 25499347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute vs cumulative benefits of metformin use in patients with type 2 diabetes and heart failure.
    Weir DL; Abrahamowicz M; Beauchamp ME; Eurich DT
    Diabetes Obes Metab; 2018 Nov; 20(11):2653-2660. PubMed ID: 29934961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.